Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOYJFK)

• Drug Name: Valrubicin Drug Info
• Synonyms: Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 454216
  ChEBI ID: CHEMBL1096885
  CAS Number: CAS 56124-62-0
  TTD Drug ID: D07IPB

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.23	0.00e+0	63/73 (86.3%)	CDKN1A;DDB2;SESN1;...
ABC transporters	2.15	0.00e+0	37/45 (82.22%)	TAP1;ABCC5;ABCG1;...
Ascorbate and aldarate metabolism	1.96	4.37e-3	15/30 (50%)	ALDH3A2;ALDH9A1;ALDH7A1;...
Lysosome	1.95	3.28e-3	115/128 (89.84%)	FUCA1;CTSA;HEXA;...
Retinol metabolism	1.95	2.62e-3	41/68 (60.29%)	CYP26B1;AOX1;CYP3A7;...
beta-Alanine metabolism	1.81	1.31e-2	25/30 (83.33%)	ABAT;ALDH3A2;ALDH9A1;...
Histidine metabolism	1.80	1.87e-2	16/22 (72.73%)	HAL;ALDH3A2;MAOB;...
Epstein-Barr virus infection	1.78	2.62e-2	189/202 (93.56%)	CDKN1A;DDB2;TAP1;...
Glycosaminoglycan degradation	1.72	4.51e-2	19/19 (100%)	HEXA;IDS;HYAL1;...
Inflammatory bowel disease	1.72	4.19e-2	58/65 (89.23%)	TLR4;MAF;STAT1;...
Oxidative phosphorylation	1.72	3.81e-2	93/133 (69.92%)	ATP5F1E;NDUFB1;NDUFA7;...
Allograft rejection	1.71	3.60e-2	32/38 (84.21%)	FAS;CD40;HLA-DQA1;...
Metabolism of xenobiotics by cytochrome P450	1.70	3.43e-2	49/77 (63.64%)	GSTM3;AKR7A2;GSTT1;...
Steroid biosynthesis	-1.70	4.48e-2	19/20 (95%)	SC5D;MSMO1;DHCR24;...
Ribosome biogenesis in eukaryotes	-1.78	1.61e-2	52/108 (48.15%)	LSG1;FCF1;TBL3;...
Spliceosome	-1.80	1.51e-2	101/150 (67.33%)	PRPF40A;SF3A1;PQBP1;...
Oocyte meiosis	-1.81	1.57e-2	90/129 (69.77%)	INS;ITPR3;CPEB1;...
Cell cycle	-1.83	1.34e-2	110/124 (88.71%)	TGFB1;CDK6;CDC23;...
Progesterone-mediated oocyte maturation	-1.89	1.34e-2	75/100 (75%)	ARAF;PIK3R1;BRAF;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼